Avita Medical (NASDAQ:RCEL) Shares Up 4.6% - Still a Buy?

Avita Medical logo with Healthcare background
Image from MarketBeat Media, LLC.

Avita Medical Inc. (NASDAQ:RCEL - Get Free Report)'s share price shot up 4.6% on Tuesday. The stock traded as high as $15.84 and last traded at $15.92. 40,973 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 344,605 shares. The stock had previously closed at $15.22.

Analyst Ratings Changes

Several research firms recently issued reports on RCEL. Weiss Ratings reissued a "sell (e+)" rating on shares of Avita Medical in a research note on Monday, September 21st. Lake Street Capital boosted their target price on shares of Avita Medical from $12.00 to $20.00 and gave the stock a "buy" rating in a research note on Friday, November 6th. BTIG Research raised their price objective on shares of Avita Medical from $15.00 to $21.00 and gave the stock a "buy" rating in a report on Friday, November 6th. Wall Street Zen upgraded shares of Avita Medical from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, TD Cowen raised their target price on shares of Avita Medical from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, November 12th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Avita Medical has an average rating of "Moderate Buy" and an average price target of $16.60.

Get Our Latest Stock Analysis on RCEL

Avita Medical Trading Up 2.0%

The firm has a market capitalization of $487.61 million, a PE ratio of -13.17 and a beta of 2.03. The stock's 50 day moving average price is $13.48 and its two-hundred day moving average price is $7.22.

Avita Medical (NASDAQ:RCEL - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. The company had revenue of $26.11 million during the quarter, compared to analysts' expectations of $22.35 million. Analysts expect that Avita Medical Inc. will post -0.94 earnings per share for the current year.

Institutional Trading of Avita Medical

Hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers purchased a new stake in Avita Medical in the third quarter valued at approximately $127,000. Harpswell Capital Advisors LLC purchased a new stake in shares of Avita Medical during the third quarter worth about $150,000. China Universal Asset Management Co. Ltd. increased its holdings in Avita Medical by 28.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company's stock worth $191,000 after purchasing an additional 3,500 shares during the last quarter. Quantinno Capital Management LP bought a new stake in shares of Avita Medical in the first quarter worth $83,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Avita Medical in the 2nd quarter valued at about $95,000. 27.66% of the stock is owned by institutional investors and hedge funds.

About Avita Medical

(Get Free Report)

AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient's healthy skin to prepare a suspension of skin cells for application to wounds. The company's RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Avita Medical Right Now?

Before you consider Avita Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avita Medical wasn't on the list.

While Avita Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines